2020/01/27 by Ching-Yao Yang, Ching‐Yao Yang, James Chih-Hsin Yang +3 · 206 citations
Biochemistry, Genetics and Molecular Biology · Medicine · #Biology #Cancer #Cancer Genomics and Diagnostics #Cancer Immunotherapy and Biomarkers #Cancer research #Chemotherapy #Disease #Druggability #Immune system #Immunology #Immunotherapy #Internal medicine #Lung Cancer Treatments and Mutations #Lung cancer #Medicine #Oncology #Targeted therapy
paper · doi:10.1146/annurev-med-051718-013524
published in Annual Review of Medicine 71(1), 117-136 (Annual Reviews)
openalex publication_date 2020/01/27 · openalex created_date 2025/10/10 · openalex updated_date 2026/08/04
The rapid evolution of treatment for advanced lung cancer is a story of how scientists have struggled to move from nonselective cytotoxic chemotherapy to personalized precision medicine. In this century, extraordinary advances have been made in the management of advanced and metastatic non-small cell lung cancer, especially in the development of small molecules targeting specific tyrosine kinase receptors and immune checkpoint inhibitors. These developments have led to a significant improvement in survival for lung cancer patients with metastatic disease. Now, the core guidelines to treat non-small cell lung cancer are based on the identification of targetable driver mutations and immune checkpoints. Continued investigations of newly identified druggable genetic alterations, explorations of biomarkers of immune checkpoint inhibitors, development of next-generation immunotherapy, and optimization of combination therapy are necessary to provide better treatment outcomes for lung cancer patients in the future.